Circulating Tfh subpopulation in very early rheumatoid arthritis

• Register: ChiCTR
• Last refreshed on: 18 April 2017
• Main ID: ChiCTR-BOC-16008925
• Date of registration: 2016-07-27
• Prospective Registration: No
• Primary sponsor: The First Hospital, Jilin University, Changchun
• Public title: Circulating Tfh subpopulation in very early rheumatoid arthritis
• Scientific title: Circulating Bcl-6+ICOS+ Tfh subpopulation correlates with disease activity in very early rheumatoid arthritis
• Date of first enrolment: 2014-06-10
• Target sample size: RA patients:22;Healthy control (HC) individuals:15;
• Recruitment status: Completed
• URL: http://www.chictr.org.cn/showproj.aspx?proj=14991
• Study type: Basic science
• Study design: Case-Control study
• Phase: Other

Countries of recruitment

China

Contacts

• Name: Xintong Hu
• Affiliation: The First Hospital of Jilin University, Changchun

• Name: Yanfang Jiang
• Affiliation: The First Hospital of Jilin University, Changchun

Key inclusion & exclusion criteria

Inclusion criteria: Plans to recruit 22 patients with VERA (<6 weeks of disease duration) at the in-patient service of the First Hospital of Jilin University (Jilin University, Changchun, China). Aged 20 to 90 years old. All the included patients fulfilled the diagnosis criteria established by the American College of Rheumatology and understand the content of the informed consent and is willing to cooperate with researchers to carry out the work.
Healthy control (HC) individuals who matched the experimental patients in terms of age, gender, and ethnicity were recruited as the control group during the same period. None of the individuals in the control group had a history of any type of chronic inflammatory disease.
Exclusion criteria: 1. treated with any disease-modifying antirheumatic drugs for any reason during the previous 6 months, and
2. diagnosed with a chronic inflammatory and autoimmune disease, such as diabetes, multiple sclerosis, inflammatory bowel disease, metabolic syndrome, hypertension, cardiovascular diseases, cancer, or recent infection.

Age minimum:
Age maximum:
Gender: Both

Health Condition(s) or Problem(s) studied

Rheumatoid Arthritis

Intervention(s)

RA patients:methotrexate;Healthy control (HC) individuals:Nil;

Primary Outcome(s)

Bcl-6+ICOS+ Tfh cells;

Source(s) of Monetary Support

This study was supported by grants from the National Natural Science Foundation of China (No. 30972610 and 81273240)